All clinical trials on the European Union Clinical Trials Register (EUCTR) must report their results in the registry within a year of completion. This site tracks who's doing this and who isn't. Learn more »
These trials completed more than 12 months ago and should have reported results. Some have, some have not.
These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.
These trials have problematic data on the registry. Details why »
|Status||Trial ID||Title||Completion date||Category|
|Completed, but no date||2007-005803-16||RANDOMIZED STUDY COMPARING INTRAVENOUS BUSULFAN (I.V. BU; BUSILVEX) PLUS FLUDARABINE (BUFLU) VERSUS INTRAVENOUS BUSULFAN PLUS CYCLOPHOSPHAMIDE (BUCY2) AS CONDITIONING REGIMENS PRIOR TO ALLOGENEIC HEMA...||bad-data|
|Completed, but no date||2008-000413-29||Randomized study with methylprednisolone 1mg/kg/day for treatment of grade I acute GvHD Studio randomizzato con methylprednisolone 1mg/kg/giorno per il trattamento della GvHD acuta di grado 1||bad-data|
|Completed, but no date||2010-022052-23||Prospective, phase II randomized study to compare busulfan-fludarabine reduced-intensity conditioning (RIC) with thiotepa-fludarabine RIC regimen prior to allogeneic transplantation of hematopoietic c...||bad-data|
|Not reported||2012-004008-37||A phase II multicentre open-label study on allogeneic stem cell transplantation from unrelated, cord-blood and family haploidentical donors in patients with active acute leukemia||2017-06-30||due-trials|
|Ongoing||2017-003530-85||Post Transplant High-Dose Cyclophosphamide as GvHD Prophylaxis in Patients Receiving 1-Antigen/Allele HLA Mismatched (7/8 matched) Unrelated Hemopoietic Cell Transplantation for Myeloid Malignancies ...||not-yet-due|
|Ongoing||2018-001344-57||Pentaglobin as early adjuvant treatment for febrile neutropenia in acute leukemia or allogeneic hematopoietic stem cell transplant patients colonized by carbapenem-resistant Enterobacteriaceae or Pseu...||not-yet-due|
|Ongoing||2020-002297-26||Phase II study on Venetoclax (VEN) plus Decitabine (DEC) (VEN-DEC) for elderly (=60 <75years) patients with newly diagnosed Acute Myeloid Leukemia (AML) elegible for allogeneic Stem Cell Transplantati...||not-yet-due|